<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808274</url>
  </required_header>
  <id_info>
    <org_study_id>2012-03</org_study_id>
    <nct_id>NCT01808274</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve</brief_title>
  <acronym>CENTERA-1</acronym>
  <official_title>Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and device success of the Edwards CENTERA
      Transcatheter Heart Valve (THV) System in patients with symptomatic, severe aortic stenosis
      who are indicated for aortic valve replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, prospective, multi-center safety and device success study. 34
      patients have been enrolled at 4 participating investigational centers in Europe. Patient
      participation will last for a minimum of 5 years. Patients will be assessed at the following
      intervals: baseline, discharge, 30 days, 6 months, 1 year and annually thereafter through 5
      years
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>30 days post-index procedure</time_frame>
    <description>NAP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success</measure>
    <time_frame>30 days</time_frame>
    <description>Device success is defined as a composite of the following events:
Factor 1: Absence of procedural mortality Factor 2: Correct positioning of a single prosthetic valve into the proper anatomical location Factor 3: Intended performance of the prosthetic heart valve (per the 30-day core lab echo assessment).
It is measured in % (favorable measures/total measures).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>device success</measure>
    <time_frame>1 year</time_frame>
    <description>Device success is defined as a composite of the following events:
Factor 1: Absence of procedural mortality Factor 2: Correct positioning of a single prosthetic valve into the proper anatomical location Factor 3: Intended performance of the prosthetic heart valve (per the 30-day core lab echo assessment).
It is measured in % (favorable measures/total measures).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>TAVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with CENTERA self-expanding valve</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards CENTERA Self-Expanding Transcatheter Heart Valve</intervention_name>
    <description>The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).</description>
    <arm_group_label>TAVR</arm_group_label>
    <other_name>TAVR</other_name>
    <other_name>TAVI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. High surgical risk: STS Score ≥ 8,EuroSCORE ≥ 15.

          2. NYHA ≥ II.

          3. Heart team (including examining cardiac surgeon) agrees on eligibility including
             assessment that TAVR is appropriate.

          4. Study patient is an adult of legal consent age.

          5. Study patient has provided written informed consent to comply with all of the study
             procedures and follow-up visits.

        Exclusion Criteria:

          1. Acute myocardial infarction ≤ 30 days before the intended treatment.

          2. Untreated clinically significant coronary artery disease requiring revascularization.

          3. Aortic valve is a congenital unicuspid or congenital bicuspid valve.

          4. Mixed aortic valve disease (with predominant aortic regurgitation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Windecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital Bern (Switzerland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Mohr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leipzig, Rhön Herzentrum (Germany)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Universitaet Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St Georg Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>042 89</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Aortic Stenosis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

